Additional study needed for RedHill's Crohn disease candidate

RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) said another Phase III trial is "most likely to be required" to support an NDA submission to FDA for Crohn disease candidate RHB-104.

On a conference call

Read the full 322 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE